Pharmaceutical Preparations · DE · CIK 1800315
Damora Therapeutics develops biologics to treat mutant calreticulin-driven blood disorders
Comparable business profile · signals at a glance
In the 90 days to Jan 2, 2026: 3 sold $23K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Schambye Hans T.Chief Executive Officer | Sell | 700 | $21.38 | $15K |
| Jan 2, 2026 | Winslow GarrettGeneral Counsel | Sell | 255 | $21.38 | $5K |
| Jan 2, 2026 | Firmani LoriChief Financial Officer | Sell | 135 | $21.41 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.